Display options
Cite
Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol. 2015;22(6):430-2doi: 10.3747/co.22.2665.
Bui, N., & Wong-Sefidan, I. (2015). Reactivation of hepatitis B virus after withdrawal of erlotinib. Current oncology (Toronto, Ont.), 22(6), 430-2. https://doi.org/10.3747/co.22.2665
Bui, N, and Wong-Sefidan, I. "Reactivation of hepatitis B virus after withdrawal of erlotinib." Current oncology (Toronto, Ont.) vol. 22,6 (2015): 430-2. doi: https://doi.org/10.3747/co.22.2665
Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. Curr Oncol. 2015 Dec;22(6):430-2. doi: 10.3747/co.22.2665. PMID: 26715877; PMCID: PMC4687665.
Copy Download .nbib Format: NLM
Share it on

Curr Oncol. 2015 Dec;22(6):430-2. doi: 10.3747/co.22.2665.

Reactivation of hepatitis B virus after withdrawal of erlotinib.

Current oncology (Toronto, Ont.)

N Bui, I Wong-Sefidan

Affiliations

  1. Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, U.S.A.

PMID: 26715877 PMCID: PMC4687665 DOI: 10.3747/co.22.2665

Abstract

Reactivation of hepatitis B virus (hbv) is a reported complication for patients undergoing chemotherapy, particularly immunochemotherapy with anti-CD20 agents such as rituximab. However, as the use of molecularly targeted agents increases, the risk of viral reactivation is less clearly defined. Here, we present the case of a 62-year-old woman with newly diagnosed EGFR mutation-positive metastatic non-small-cell lung cancer (nsclc). Per interview, our patient had a remote history of hbv infection. She was started on erlotinib and developed profound diarrhea leading to renal failure that required hospital admission and temporary discontinuation of erlotinib. At 8 days after erlotinib cessation, she had a marked spike in her liver function tests, with viral serologies that were consistent with hbv reactivation. Although erlotinib and other tyrosine kinase inhibitors (tkis) are not classically associated with hbv reactivation, hbv reactivation can occur even in the setting of tki withdrawal. Before tki initiation, careful patient screening in those at risk for hbv should be performed to attenuate preventable hepatotoxicity and to differentiate between other causes of hepatotoxicity (for example, drug-induced toxicity).

Keywords: EGFR mutation; Non-small-cell lung cancer; erlotinib; hepatitis B reactivation

References

  1. J Clin Oncol. 2010 Jul 1;28(19):3199-202 - PubMed
  2. Ann Hematol. 2014 Jun;93(6):1075-6 - PubMed
  3. Gastroenterology. 1991 Jan;100(1):182-8 - PubMed
  4. World J Gastroenterol. 2013 Feb 28;19(8):1318-21 - PubMed
  5. Onco Targets Ther. 2014 Jul 01;7:1185-93 - PubMed
  6. J Clin Oncol. 2015 Jul 1;33(19):2212-20 - PubMed
  7. J Clin Oncol. 2013 Mar 1;31(7):895-902 - PubMed
  8. Q J Med. 1989 Oct;73(270):911-7 - PubMed
  9. Arch Intern Med. 1985 Jul;145(7):1313-4 - PubMed
  10. JOP. 2007 Jan 09;8(1):39-43 - PubMed
  11. J Med Virol. 2000 Nov;62(3):299-307 - PubMed
  12. Blood. 2002 Apr 1;99(7):2324-30 - PubMed
  13. Eur Respir Rev. 2014 Mar 1;23(131):92-105 - PubMed
  14. Clin Adv Hematol Oncol. 2008 Mar;6(3):191-199 - PubMed
  15. Clin Epidemiol. 2011;3:139-48 - PubMed
  16. Case Rep Oncol. 2012 Sep;5(3):515-9 - PubMed
  17. JAMA. 2013 Oct 23;310(16):1664 - PubMed
  18. Clin Gastroenterol Hepatol. 2007 Aug;5(8):917-20 - PubMed

Publication Types